Clinical Trials Logo

Multiple Sclerosis clinical trials

View clinical trials related to Multiple Sclerosis.

Filter by:

NCT ID: NCT00927108 Withdrawn - Multiple Sclerosis Clinical Trials

Rajavtihi Neuronal Adult Stem Cells Project

RNASc
Start date: July 2009
Phase: Phase 2
Study type: Interventional

To study the success of Oligodendrocyte progenitor cell culture project in Rajavithi Hospital to identify an unlimited clone human neuronal progenitor stem cells from the human brain in the Biomolecular Research Center. This study aims to produce the reproductive clone of neuronal development protocols and advance projects. Neuronal cells such as pyramidal cells, oligodendrocyte, and dopaminergic neuron differentiation protocol/projects for treatment of Alzheimer's disease, Multiple sclerosis, and Parkinson's disease respectively in next phase of clinical trials.

NCT ID: NCT00922831 Withdrawn - Multiple Sclerosis Clinical Trials

Progression of Cognitive and Physical Symptoms in Multiple Sclerosis

Start date: August 2008
Phase:
Study type: Observational

The purpose of this study is to look at multiple sclerosis patients process of awareness, learning, and judging status over a 3 year time period.

NCT ID: NCT00919217 Recruiting - Clinical trials for Relapsing Remitting Multiple Sclerosis

Exploratory Study on the Timing of Multiple Sclerosis (MS) Symptoms

Start date: August 2008
Phase:
Study type: Observational

The investigators' overall hypothesis is that appearance or worsening of relapsing-remitting multiple sclerosis (RR-MS) symptoms are affected by various factors including stress, hormonal cycles, illness and missed medications.

NCT ID: NCT00917839 Recruiting - Clinical trials for Relapsing-Remitting Multiple Sclerosis

The Neuroprotective Effect of Lamotrigine and Interferon Beta 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Start date: June 2009
Phase: Phase 2
Study type: Interventional

This study is designed to evaluate the neuroprotective effect of lamotrigine in the combination of interferon beta 1a once weekly intramuscular in patients with relapsing-remitting multiple sclerosis.

NCT ID: NCT00915577 Completed - Multiple Sclerosis Clinical Trials

Patient Satisfaction Study of Single-Use Autoinjector for the Delivery of Pre-Filled Avonex Syringe

Start date: August 2005
Phase: Phase 3
Study type: Interventional

Determine patient satisfaction with the single-use autoinjector for the delivery of pre-filled Avonex syringe.

NCT ID: NCT00915460 Completed - Multiple Sclerosis Clinical Trials

Open-Label Safety Extension Study of Avonex

Start date: September 1999
Phase: Phase 4
Study type: Interventional

To collect data on serious adverse events which occur during extended treatment with Avonex in subjects at high risk for developing multiple sclerosis (MS) and in subjects with secondary progressive MS.

NCT ID: NCT00914758 Enrolling by invitation - Clinical trials for Relapsing Remitting Multiple Sclerosis

Comparison of Campath and Rebif Treatment on Cognition in Multiple Sclerosis (MS)

Start date: March 2009
Phase: N/A
Study type: Observational

People with multiple sclerosis (MS) often experience problems with cognitive functioning, which can be debilitating and interfere with their daily functioning. However, research has shown that MS disease modifying agents have had some success in treating cognitive problems. The main purpose of this research study is to investigate how well two medicines (alemtuzumab (Campath®) and interferon beta-1a (Rebif®)) work in treating MS-related cognitive problems (e.g., attention, memory, speed of thinking). Participants enrolled will be assessed prior to their first study-related medication dose and re-assessed throughout treatment. It is expected that participants taking Campath® will demonstrate relative stability in cognitive functioning relative to those taking Rebif®. Specifically, the cognitive performance of Rebif® participants will decline somewhat over time, but the cognitive performance of Campath® participants will remain stable.

NCT ID: NCT00914290 Completed - Multiple Sclerosis Clinical Trials

A Study With IPX056 in Subjects With Spasticity Associated With Multiple Sclerosis

Start date: April 2009
Phase: Phase 2
Study type: Interventional

To explore the safety and efficacy of IPX056 compared with baclofen tablets for alleviation of symptoms of spasticity associated with multiple sclerosis (MS).

NCT ID: NCT00913666 Completed - Multiple Sclerosis Clinical Trials

Pharmacodynamic Study to Better Understand the Therapeutic Response and Immunomodulatory Effects of Avonex in Multiple Sclerosis (MS) Patients and Healthy Volunteers

Start date: November 2002
Phase: Phase 4
Study type: Interventional

This study will look at differences in bioanalytical measures among different groups of MS patients and Healthy Volunteers, when administered interferon beta-1a.

NCT ID: NCT00913510 Terminated - Multiple Sclerosis Clinical Trials

Efficacy of Clean Intermittent Catheterization (CIC) in Multiple Sclerosis (MS) Patients With Bladder Dysfunction

Start date: December 2009
Phase: N/A
Study type: Interventional

The aims of this prospective, randomized study are: - To assess the effect of clean intermittent catheterization (CIC) - To investigate if MS patients will have symptom reduction (urgency, frequency, nocturia and incontinence) when using CIC in combination with anticholinergic drugs - To identify at what volume of Postvoid Residual (PVR) urine, starting CIC improves bladder control and QoL - To increase the evidence of CIC, and support clinical guidelines of bladder management in MS patients